Skip to main content

Table 2 Multivariate Cox regression analysis of the clinicopathogical parameters for overall survival and progression free survival

From: Prognostic and therapeutic value of disruptor of telomeric silencing-1-like (DOT1L) expression in patients with ovarian cancer

 

Overall survival

 

Progression free survival

 

HR

95% CI

P

HR

95% CI

P

FIGO stage (early stage vs. advanced stage)

1.127

0.357–3.562

0.838

1.744

0.576–5.288

0.325

Histologic grade (well vs. poor and moderate)

0.615

0.256–1.475

0.276

0.904

0.393–2.077

0.811

Ascites (no vs. yes)

0.850

0.381–1.897

0.692

0.667

0.337–1.323

0.247

LN metastasis (no vs. yes)

0.924

0.460–1.856

0.823

0.786

0.410–1.506

0.468

Age (≤50 vs. >50 years)

2.920

1.466–5.815

0.002

2.403

1.302–4.435

0.005

Preoperative CA125 (U/ml) (≤600 vs. >600)

0.548

0.280–1.073

0.079

0.327

0.177–0.607

0.000

DOT1L expression (low vs. high)

4.705

2.160–10.248

0.000

8.884

3.974–19.861

0.000

  1. HR hazard ratio, CI confidence interval